Company profile
Genomic Labs Ltd
GenomeKey - Unlocking DNA
Using whole genome sequencing and novel machine learning, GenomeKey diagnoses bacterial presence, species and antimicrobial resistance in only hours, not days, at low cost.
Latest accounts
Financial period: 1 Sep 2024 to 31 Aug 2025
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts filed
AccountsLast accounts made up date
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzQ0NDI0NjcyMmFkaXF6a2N4
Published 20 Nov 2024 08:58
Appoint Person Director Company With Name Date
OfficersAP01 | Transaction MzQ0NDMwOTQ2MWFkaXF6a2N4
Published 20 Nov 2024 05:46
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQ0NDMwOTI4MGFkaXF6a2N4
Published 20 Nov 2024 05:42
Confirmation Statement With Updates
Confirmation-statementCS01 | Transaction MzQzMjUwMjg5NGFkaXF6a2N4
Published 16 Aug 2024 13:20
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
Continuous Contamination Monitoring through Single-Cell Sequencing for Pharmaceutical Quality Control: Fast-track to Pilot Deployment
1 Jul 2025 to 28 Feb 2026
GenomeKey is developing a revolutionary environmental monitoring system for pharmaceutical manufacturing that combines proprietary microfluidic concentration technology with next-generation DNA sequencing to enable rapid detection and identification of microbial contaminants. Current pharmaceutical quality control relies on traditional culture-based testi...
Fighting antimicrobial resistant infections - A next-generation diagnostic device
1 Jul 2023 to 30 Jun 2025
GenomeKey is developing a next-generation diagnostic device for bacterial blood infections. Our diagnostic will result in earlier and more accurate detection and diagnosis of bacterial sepsis, and faster antimicrobial susceptibility results, leading to better treatment, patient outcomes and considerable treatment cost savings. In addition, our device will...
Combatting Antimicrobial Resistance with Next-Generation Diagnostics for Sepsis
1 May 2022 to 31 Oct 2023
GenomeKey is developing a next-generation point-of-care diagnostic device for bacterial blood infections in cases of sepsis. Our diagnostic will result in earlier and more accurate detection and diagnosis of bacterial sepsis, and faster antimicrobial susceptibility results, leading to better treatment, patient outcomes and considerable treatment cost savi...
Next-generation Diagnostics for Bacterial Co-infection of COVID-19
1 Jan 2021 to 31 Mar 2021
GenomeKey determines how to treat Sepsis in hours, rather than days. This is important because Sepsis now kills more people than cancer, and can kill within hours. For a patient admitted to a hospital today, they would wait 3 days before the doctor knows which antibiotic will fight the infection. GenomeKey reduces this time using cutting edge machine lear...